Pfizer Reports Phase 2b Results for Monthly GLP-1 Drug Berobenatide
Pfizer's experimental GLP-1 receptor agonist berobenatide showed strong blood-sugar control and weight-loss effects in a Phase 2b trial. The company said the drug was generally well tolerated and supported further testing of once-monthly dosing.
thehindubusinessline.comPfizer announced Phase 2b trial results for its GLP-1 receptor agonist berobenatide. The study tested monthly dosing in adults with type 2 diabetes. The company reported robust reductions in blood glucose and body weight. Tolerability data showed side-effect rates consistent with other GLP-1 medicines.
Participants received one injection each month for the study duration. Researchers compared several dose levels against placebo. The company stated that efficacy and safety findings support advancing the candidate into later-stage trials.
Pfizer has not disclosed the start date for a Phase 3 program.
Further details on trial enrollment criteria and timelines are expected in future updates.
